SPARC expression in patients with high-risk localized soft tissue sarcoma treated on a randomized phase II trial of neo/adjuvant chemotherapy

[1]  B. Dörken,et al.  SPARC expression in resected pancreatic cancer patients treated with Gemcitabine: results from the CONKO-001 study. , 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  D. Reinke,et al.  A randomised, open-label, phase II study of neo/adjuvant doxorubicin and ifosfamide versus gemcitabine and docetaxel in patients with localised, high-risk, soft tissue sarcoma. , 2015, European journal of cancer.

[3]  M. Hidalgo,et al.  SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis of the Phase III MPACT Trial , 2015, Clinical Cancer Research.

[4]  S. Millis,et al.  Multi-platform profiling of over 2000 sarcomas: Identification of biomarkers and novel therapeutic targets , 2015, Oncotarget.

[5]  Y. Ba,et al.  Change of SPARC expression after chemotherapy in gastric cancer , 2015, Cancer biology & medicine.

[6]  P. Fasching,et al.  Expression of secreted protein acidic and rich in cysteine (SPARC) in breast cancer and response to neoadjuvant chemotherapy. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  Hong Yin,et al.  Preclinical evaluation of nanoparticle albumin‐bound paclitaxel for treatment of pediatric bone sarcoma , 2014, Pediatric blood & cancer.

[8]  R. Nagle,et al.  Serum protein acidic and rich in cysteine (SPARC) as a prognostic marker in soft tissue sarcomas , 2013, Clinical Sarcoma Research.

[9]  A. Maitra,et al.  Gemcitabine plus nab-paclitaxel is an active regimen in patients with advanced pancreatic cancer: a phase I/II trial. , 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  P. Soon-Shiong,et al.  SPARC Expression Correlates with Tumor Response to Albumin-Bound Paclitaxel in Head and Neck Cancer Patients. , 2009, Translational oncology.

[11]  M. Tang,et al.  SPARC in cancer biology: its role in cancer progression and potential for therapy. , 2008, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[12]  Andrea S. Llera,et al.  The role of the matricellular protein SPARC in the dynamic interaction between the tumor and the host , 2008, Cancer and Metastasis Reviews.

[13]  J. Squire,et al.  Effects of THBS3, SPARC and SPP1 expression on biological behavior and survival in patients with osteosarcoma , 2006, BMC Cancer.

[14]  G. Watkins,et al.  Increased levels of SPARC (osteonectin) in human breast cancer tissues and its association with clinical outcomes. , 2005, Prostaglandins, leukotrienes, and essential fatty acids.

[15]  E. Sage,et al.  SPARC and tumor growth: Where the seed meets the soil? , 2004, Journal of cellular biochemistry.

[16]  Alan Mackay,et al.  Expression profiling of purified normal human luminal and myoepithelial breast cells: identification of novel prognostic markers for breast cancer. , 2004, Cancer research.